Aquestive Therapeutics, Inc.

AQST Nasdaq SEC CIK 1398733
Follow Aquestive Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $7.6M −41% vs same quarter last year
Net income −$16.5M −6.8% vs same quarter last year
EPS, diluted −$0.13 +7.1% vs same quarter last year
Operating cash flow −$7M +44.3% vs same quarter last year
Revenue by quarter
$11.9M
$8.7M
$10M
$12.8M
$13M
$14.4M
$13.8M
$7.6M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$100M−$50M$0$50M$100MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$44.5M−$83.8M
FY24$57.6M−$44.1M
FY23$50.6M−$7.9M
FY22$47.7M−$54.4M
FY21$50.8M−$70.5M
FY20$45.8M−$55.8M
FY19$52.6M−$66.2M
FY18$67.4M−$61.4M
FY17$66.9M−$8.9M
FY16--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−200%−100%0%100%FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2558.3%−159.5%−188.1%
FY2469%−53.5%−76.7%
FY2358.8%−29.9%−15.6%
FY2259.3%−88.2%−114.1%
FY21-−68.2%−138.8%
FY2071.7%−93.6%−121.7%
FY1961.3%−100.1%−125.9%
FY18-−72.6%−91%
FY17-−0.2%−13.4%
FY16---
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0$20MFY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$53M
FY24−$35.9M
FY23−$7.4M
FY22−$10.8M
FY21−$33.9M
FY20−$46M
FY19−$60.9M
FY18−$14.8M
FY17$3.8M
FY16-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Aquestive Therapeutics
  • Healthcare median
−200%−150%−100%−50%0%FY17FY19FY21FY23FY25
Show the numbers
YearAquestive TherapeuticsHealthcare median
FY25−188.1%−30.6%
FY24−76.7%−47%
FY23−15.6%−58%
FY22−114.1%−80.4%
FY21−138.8%−71.8%
FY20−121.7%−62.2%
FY19−125.9%−46.2%
FY18−91%−49.6%
FY17−13.4%−45.9%
FY16-−36%